Scilex Holding (SCLX) Enterprise Value (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Enterprise Value of -$149.9 million for Q1 2026, down 2484.9% year-over-year from $6.3 million in Q1 2025, and down 891.17% on a QoQ basis from -$15.1 million in Q4 2025.
Scilex Holding (SCLX) Enterprise Value (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Enterprise Value for 7 consecutive years, with -$149.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 2484.9% year-over-year to -$149.9 million; the TTM figure through Mar 2026 stood at -$149.9 million (down 2484.9% YoY), while the FY2025 annual figure was -$15.1 million, down 362.29% from the prior year.
- Enterprise Value came in at -$149.9 million for Q1 2026 at Scilex Holding, down from -$15.1 million in the prior quarter.
- The five-year high for Enterprise Value was -$69922.0 in Q3 2022, with the low at -$149.9 million in Q1 2026.
- Average Enterprise Value over 5 years is -$30.6 million, with a median of -$4.1 million recorded in 2025.
- The largest YoY upside for Enterprise Value was 98.48% in 2022 against a maximum downside of 55034.43% in 2022.
- Year by year, Enterprise Value stood at -$2.2 million in 2022, then plunged by 79.53% to -$3.9 million in 2023, then grew by 16.55% to -$3.3 million in 2024, then sank by 362.29% to -$15.1 million in 2025, then slumped by 891.17% to -$149.9 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$149.9 million, -$15.1 million, and -$3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.35 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -7.89 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 315.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -149.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -149.92 Mn |
| Dec 31, 2025 | -15.13 Mn |
| Sep 30, 2025 | -3.68 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Mar 31, 2025 | -5.80 Mn |
| Dec 31, 2024 | -3.27 Mn |
| Sep 30, 2024 | -77,000.00 |
| Jun 30, 2024 | -6.89 Mn |
| Mar 31, 2024 | -1.82 Mn |
| Dec 31, 2023 | -3.92 Mn |
| Sep 30, 2023 | -2.00 Mn |
| Jun 30, 2023 | -34.12 Mn |
| Mar 31, 2023 | -5.10 Mn |
| Dec 31, 2022 | -2.18 Mn |
| Sep 30, 2022 | -69,922.00 |
| Jun 30, 2022 | -142.04 Mn |
| Mar 31, 2022 | -140.58 Mn |
| Dec 31, 2021 | -143.75 Mn |
| Sep 30, 2021 | -115,642.00 |
| Jun 30, 2021 | -257,621.00 |